NCT05134948View on ClinicalTrials.gov

A Study to Assess Relatlimab and Nivolumab Fixed-dose Combination in Chinese Participants With Advanced Solid Tumors

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

November 30, 2021

Primary Completion Date

September 1, 2025

Study Completion Date

October 22, 2025

Conditions
Advanced Solid Tumors
Interventions
DRUG

BMS-986213

Specified dose on specified days

Trial Locations (2)

100142

Local Institution - 0001, Beijing

350014

Local Institution - 0002, Fuzhou

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY